{"id":59005,"date":"2024-06-25T11:04:28","date_gmt":"2024-06-25T11:04:28","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=59005"},"modified":"2024-07-03T17:21:52","modified_gmt":"2024-07-03T17:21:52","slug":"levels-of-expression-of-hsp70-and-inos-and-effect-of-artemisia-sieberi-a-herba-alba-on-activity-of-hypothalamic-pituitary-thyroid-hpt-axis-in-diabetic-rats","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol17no2\/levels-of-expression-of-hsp70-and-inos-and-effect-of-artemisia-sieberi-a-herba-alba-on-activity-of-hypothalamic-pituitary-thyroid-hpt-axis-in-diabetic-rats\/","title":{"rendered":"Levels of Expression of Hsp70 and iNOS and Effect of Artemisia Sieberi (A. herba-alba) on Activity of Hypothalamic-Pituitary-Thyroid (HPT) Axis in Diabetic Rats"},"content":{"rendered":"\n

Introduction<\/strong><\/p>\n\n\n\n

Artemisia sieberi <\/em>(A. herba-alba<\/em>) belongs to the Asteraceae\n(Compositae) family and includes annual, perennial, and biennial plants1<\/sup>. Artemisia\nherba-alba<\/em> is a short shrub usually found in Northern Africa and the\nMiddle East. The parts that grow above the ground are used as medicine2<\/sup>. The herb is used\ntraditionally to treat wounds, parasites (especially helminths), diabetes,\nrespiratory and intestinal disorders, and injuries2<\/sup>. Moreover, several Artemisia<\/em> herbs have historically been\nused to treat seizures and their efficacy has been proven by in vivo<\/em> animal trials3,4,5<\/sup>. The Artemisia<\/em> species have been studied in vitro<\/em> and in vivo<\/em>, as well as in clinical trials, for their anticancer,\nantimalarial, antibacterial, antiviral, and antidiabetic properties6<\/sup>. Vegetables,\nculinary herbs, and medicinal plants are commonly used to control diabetes in\nJordan, where traditional medicine is an essential component of primary health\ncare7<\/sup>. <\/p>\n\n\n\n

The synthesis of nitric oxide (NO) involves enzymes that convert the amino acid L-arginine into NO8<\/sup>. The inducible nitric oxide synthase (iNOS) is a key physiological signaling molecule that regulates insulin production, angiogenesis, nociception, inflammation, and pain8,9<\/sup>. Enzymatic synthesis of NO is controlled by isoenzymes, including endothelial, neuronal, and inducible isoforms8<\/sup>. The concentration of the resultant NO depends on numerous parameters, which mainly include the isoform involved in NO production and duration of the production process8,9<\/sup>. The iNOS is more likely to generate NO than other isoforms 10<\/sup>. Diabetic rats have high levels of iNOS8,9,10<\/sup>.<\/p>\n\n\n\n

The Heat Shock\nProtein 70 is one of the central components of thecellular network of molecular chaperones. It is naturally\ngenerated in lymphocytes, macrophages, epithelial cells, dendrites, muscles,\nand hepatocytes. Having a molecular mass of 70 kDA, this protein molecule has a\nrole in regulating homeostasis of other proteins and is dependent in its action\non adenosine triphosphate (ATP)11<\/sup>. Some\nHsp70 chaperones are characterized by their genes and cell sites. Both Hsp70\nand the heat shock 70 protein (Hsc70) are found in the nucleus and cytoplasm;\nthe binding immunoglobulin protein (BiP) Grp78 is placed in the endoplasmic\nreticulum (ER) and mitochondrial Hsp70 (mtHsp70) Grp75 is located in the\nmitochondria11, 12<\/sup>.\nChanges in Hsp70 expression have been seen in people with obesity and metabolic\ndisorders, including type 2 diabetes as evidenced by results of several\nstudies. According to some studies, increasing insulin sensitivity through\nHsp70 modulation might affect blood glucose levels12,13,14<\/sup>. The\nhypothalamus-pituitary-periphery (HPT) feedback loop regulates the production,\nstoring, and secretion of thyroid hormones by the thyroid gland. The presence\nof two crucial trace elements\u2014selenium and iodin\u2014is necessary for these\nprocesses1<\/sup>.\nThe thyroid-stimulating hormone (TSH), which is secreted by the anterior\npituitary gland, is the primary stimulator of thyroid hormone synthesis. It\nenhances all the processes required for thyroid hormone biosynthesis, including\nprotein biosynthesis, intra-thyroidal iodide organification, and stimulation of\nthyroglobulin (Tg) release15<\/sup>. Diabetes mellitus (DM) and thyroid problems are\nassociated with endocrine system dysfunction. Research16<\/sup> has shown that\ndiabetes and thyroid diseases frequently co-exist in individuals. Considering\ntheir roles in cellular metabolism, insulin and thyroid hormone excesses or\ndeficiencies can lead to functional abnormalities in the other hormones16<\/sup>. Bearing this in\nmind, this study was carried out to evaluate the levels of expressions of the\nHsp70 and iNOS biomarkers in dilute oil extract of A. herba-alba<\/em> (AHA) and their effects on the action of the\nhypothalamic-pituitary-thyroid (HPT) axis in rats suffering from diabetes.<\/p>\n\n\n\n

Experimental Part<\/strong><\/p>\n\n\n\n

Preparation of oil<\/strong><\/p>\n\n\n\n

Artemisia\nsieberi (A. herba-alba)<\/em> aerial parts were used to\nextract the essential oil using the extraction method described in references17,18<\/sup>. Dry parts of\nthis plant were cut into 0.5 mm pieces and allowed to air dry in the dark at\nroom temperature for five days. Afterwards, a mass corresponding to 200g of the\ndried material was hydrodistilled for 3 h using Clevenger apparatus. The oil\nyield of the dried tops (leaves, stems, and flowers) was 1.1% (v\/w).<\/p>\n\n\n\n

Diabetes induction in rats<\/strong><\/p>\n\n\n\n

For this\nstudy, adult rats weighing 150\u2013200 g were bought from the Jordan University of\nScience and Technology (JUST) Faculty of Medicine’s central animal house. The\nanimals were maintained on a 12-hour light-dark cycle. Water and food were\navailable ad libitum<\/em>. A stock diet\nmeal consisting of 50% wheat, 21% maize, 20% soybean, 8% concentrated protein,\nand 1% of a combination of salts, vitamins, and dicalcium phosphate was\nsupplied to the rats, who were kept in normal metal cages with ten rats per\ncage. Struggle and restraint were minimized to avoid the influence of stress on\nthe test results as highlighted in18<\/sup>. The rats were administered intraperitoneal\ninjections of alloxan monohydrate (BOH Chemicals Ltd, England) dissolved in\nfresh normal saline at a dose of 150 ml per kg body weight (BW) after fasting for 18\nh. Rats in this study were classified as diabetics if their blood glucose concentrations\nranged between 200 and 450 mg\/100 ml. 17, 18<\/sup>.<\/p>\n\n\n\n

Experimental design<\/strong><\/p>\n\n\n\n

50 rats\nwere randomly divided into five experimental groups of 10 each. Normal rats\nhave been split into two groups: 1 and 2. Group 1 rats received dimethyl\nsulfoxide (DMSO) at a 0.5 mL\/kg dosage and were used as the negative control\ngroup. A. sieberi <\/em>essential oil extract was administered by gavage to group 2 at 80 mg\/kg. Rats with alloxan-induced\ndiabetes were divided into three groups: 3, 4, and 5. Group 3 rats were only\ngiven DMSO at a 0.5 mL\/kg dosage. Meanwhile, Group 4 rats received treatment\nwith dilute AHA oil extract (80 mg\/kg), whereas Group 5 rats received Metformin (14.2 mg\/kg). The\nMetformin was obtained from Bristol-Myers Squibb Company in the United Kingdom.\nFor six weeks, the essential oil extract and Metformin were given daily via an intragastric\ntube. Rats in each group received the recommended treatment for 6 weeks, with\nunlimited access to water and food during the trial. Blood samples were\nobtained from the rats at the end of the study period after the heart puncture\nprocedure, and tissues\nspecimens were collected from the thyroid gland to look at histological\nalterations. The\nmice were killed by cervical dislocation after the study procedure while\nunder light ether anesthesia. The experiment was conducted in compliance\nwith the guidelines of the animal ethics committee of JUST, which were expressed\nin accordance with international standard principles for laboratory animal use\nand care (Number 27045128\/17).<\/p>\n\n\n\n

Determination of thyroid hormone <\/strong><\/p>\n\n\n\n

The micro particle enzyme immunoassay (MEIA)\nis the basis for quantification of the Axsym thyroid hormone (triiodothyronine\n(T3), thyroxine (T4), and TSH). The following order is followed while pipetting\nthe axsym-free (T3, T4, and TSH) reagents and samples. The sampling\nprobe pipettes the sample and the assay (T3, T4, and TSH) chemicals that are\nneeded for a single test into different reaction vessel (RV) wells. The RV is\nmoved right away into the processing facility 18<\/sup>. Using the processing probe, further\npipetting is performed at the processing center. An antibody-antigen\ncombination is formed when the sample and anti-T3, anti-T4, and anti-TSH-coated\nmicro particles are pipetted into one well of the RV. An aliquot of the\nreaction mixture\ncomprising T3, T4, and TSH bound to anti-T3, anti-T4, and anti-TSH-coated micro\nparticles was added to the matrix cell. The glass fiber matrix and the micro particles\nform an irreversible bond. To remove unbound components, solubilizer solution\nwas used to wash the matrix cell. When applied to the matrix cells, T3-alkaline\nphosphatase interacts with the open antibody binding sites. Unbound materials\nare eliminated by washing the matrix cell. After adding the substrate, that is\n4-methyumbelliferyl phosphate, to the matrix cell, the MEIA optical assembly\nmeasures the fluorescence18<\/sup>.<\/p>\n\n\n\n

T3, T4, and TSH levels<\/strong><\/p>\n\n\n\n

AxSYM-free T3 and T4 MEIA measures free T3 quantitatively in human blood or plasma using the AxSYM analyzer17,18<\/sup>. The AXSYM 3rd Generation TSH Test is a useful method of concluding thyroid function, identification of thyroid conditions, and management of thyroid-related illnesses18<\/sup>.  <\/p>\n\n\n\n

Immunohistochemistry<\/strong> study   <\/strong><\/p>\n\n\n\n

Schematic Overview of Immunohistochemistry:<\/p>\n\n\n\n\n\n
\"\"<\/td>\n\n

Chart 1: Schematic Overview of Immunohistochemistry<\/strong><\/p>\n

<\/p>\n

Click here to view Chart<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

Interpretation of the Results<\/strong><\/p>\n\n\n\n

The resulting number\nof pixels that represented the immunological reaction was divided by the total\nnumber of pixels. Following that, the number of pixels with brown color, which\nis the color of the marker in the present study, was determined and divided by the\nwhole number of pixels to estimate the expression of HSP70 and iNOS based on the interpretation\nof output of Adobe Photoshop Version: 22.3.19<\/sup>.<\/p>\n\n\n\n

Statistical\nanalysis<\/strong><\/p>\n\n\n\n

Results are\nexpressed as mean \u00b1SE. One-way analysis of variance (ANOVA) was used to estimate\nstatistical differences by using SPSS version 22. A value of p <\n0.05 was considered significant18,20<\/sup>. Descriptive statistics for HSP70 for every group\nwere calculated then presented as \u201cMean \u00b1 Standard deviation\u201d.<\/p>\n\n\n\n

Results <\/strong><\/p>\n\n\n\n

Effects of Artemisia<\/em>\nand Metformin on\nT3, T4, and TSH levels in diabetic rats<\/strong><\/p>\n\n\n\n

The study\nfound significant drops (p < 0.05) in blood T3, T4, and TSH levels in the\ndiabetic rats below the corresponding levels in the control group (Table 1). Rats\nin the control group have substantially increased blood T4, T3, and TSH levels\n(p < 0.05) than the comparable values in the diabetic rats. Furthermore,\ncompared to the control rats, the diabetic rats had greater blood TSH levels.\nThese findings imply that AHA oil therapy significantly raised the control\ngroup’s blood T4 levels (p < 0.05).<\/p>\n\n\n\n

Table 1: Levels of TSH, T3, and T4 in the control and diabetic rats.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

T4<\/sub><\/strong><\/p>\n

(nmol\/L)<\/strong><\/p>\n<\/td>\n

\n

T3<\/sub><\/strong><\/p>\n

(nmol\/L)<\/strong><\/p>\n<\/td>\n

\n

TSH<\/strong><\/p>\n

(ng\/ml)<\/strong><\/p>\n<\/td>\n

\n

N<\/em><\/strong><\/p>\n<\/td>\n

\n

Group<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

48.65 \u00b1 2.45<\/p>\n<\/td>\n

\n

1.46 \u00b1 0.05<\/p>\n<\/td>\n

\n

0.93 \u00b1 0.02<\/p>\n<\/td>\n

\n

10<\/p>\n<\/td>\n

\n

1.      Untreated Control<\/p>\n<\/td>\n<\/tr>\n

\n

54.82\u00b1 4.84*<\/p>\n<\/td>\n

\n

2.21\u00b1 0.13*<\/p>\n<\/td>\n

\n

1.67\u00b10.01*<\/p>\n<\/td>\n

\n

10<\/p>\n<\/td>\n

\n

2.      Control treated with dilute AHE oil<\/p>\n<\/td>\n<\/tr>\n

\n

30.58\u00b1 2.27<\/p>\n<\/td>\n

\n

0.82 \u00b1 0.03*<\/p>\n<\/td>\n

\n

0.48 \u00b1 0.03*<\/p>\n<\/td>\n

\n

10<\/p>\n<\/td>\n

\n

3.      Rats with alloxan-induced diabetes<\/p>\n<\/td>\n<\/tr>\n

\n

40.66 \u00b1 1.28**<\/p>\n<\/td>\n

\n

1.04 \u00b1 0.06**<\/p>\n<\/td>\n

\n

0.83 \u00b1 0.04**<\/p>\n<\/td>\n

\n

10<\/p>\n<\/td>\n

\n

4.      Diabetic rats treated with dilute AHE oil<\/p>\n<\/td>\n<\/tr>\n

\n

38.54 \u00b1 1.43**<\/p>\n<\/td>\n

\n

1.08 \u00b1 0.07**<\/p>\n<\/td>\n

\n

0.76 \u00b1 0.03**<\/p>\n<\/td>\n

\n

10<\/p>\n<\/td>\n

\n

5.      Diabetic rats treated with Metformin<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Values are the mean values \u00b1 standard deviation of 10 rats.<\/p>\n

* Statistically significant when compared to the control and vehicle groups, i.e., Groups 1 and 2, at \u03b1 = 0.05.  <\/p>\n

** Statistically significant when compared to the rats with alloxan-induced diabetes (Group 3) at \u03b1 = 0.05.<\/p>\n\n\n

Immunohistochemistry results<\/strong><\/p>\n\n\n\n

Expression rates of hsp70 in control and diabetic\ngroups <\/strong><\/p>\n\n\n\n

Our results\ndemonstrate that diabetes significantly decreased Hsp70 expression in the\nkidneys and liver (p <\/em>< 0.05).\nDiabetes had a molecular impact on the liver and kidneys. In addition, there\nwas no significant difference (p<\/em> >\n0.05) in Hsp70 expression in the thyroid gland between diabetes and\nnon-diabetic rats (Table 2).<\/p>\n\n\n\n

Table 2: Levels of Hsp70 expression in rats of the control and diabetic groups.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Hsp70 Expression<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Liver<\/strong><\/p>\n<\/td>\n

\n

Kidney<\/strong><\/p>\n<\/td>\n

\n

Thyroid gland<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Control Rats<\/strong><\/p>\n<\/td>\n

\n

Diabetic Rats<\/strong><\/p>\n<\/td>\n

\n

Control Rats<\/strong><\/p>\n<\/td>\n

\n

Diabetic Rats<\/strong><\/p>\n<\/td>\n

\n

Control Rats<\/strong><\/p>\n<\/td>\n

\n

Diabetic Rats<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

0.40<\/p>\n<\/td>\n

\n

0.08<\/p>\n<\/td>\n

\n

0.40<\/p>\n<\/td>\n

\n

0.15<\/p>\n<\/td>\n

\n

0.30<\/p>\n<\/td>\n

\n

0.10<\/p>\n<\/td>\n<\/tr>\n

\n

0.39<\/p>\n<\/td>\n

\n

0.10<\/p>\n<\/td>\n

\n

0.39<\/p>\n<\/td>\n

\n

0.13<\/p>\n<\/td>\n

\n

0.31<\/p>\n<\/td>\n

\n

0.09<\/p>\n<\/td>\n<\/tr>\n

\n

0.38<\/p>\n<\/td>\n

\n

0.09<\/p>\n<\/td>\n

\n

0.38<\/p>\n<\/td>\n

\n

0.14<\/p>\n<\/td>\n

\n

0.32<\/p>\n<\/td>\n

\n

0.08<\/p>\n<\/td>\n<\/tr>\n

\n

0.42<\/p>\n<\/td>\n

\n

0.11<\/p>\n<\/td>\n

\n

0.37<\/p>\n<\/td>\n

\n

0.16<\/p>\n<\/td>\n

\n

0.35<\/p>\n<\/td>\n

\n

0.11<\/p>\n<\/td>\n<\/tr>\n

\n

0.39<\/p>\n<\/td>\n

\n

0.10<\/p>\n<\/td>\n

\n

0.36<\/p>\n<\/td>\n

\n

0.12<\/p>\n<\/td>\n

\n

0.29<\/p>\n<\/td>\n

\n

0.99<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n

The effects of Metformin and dilute AHA oil on levels of Hsp70 expression.<\/strong><\/p>\n\n\n\n

The outcomes of the experiment (Table 3) revealed that both Metformin and dilute AHA oil treatments at significant (p <\/em>< 0.05) raised the levels of Hsp70 expression in the livers, kidneys, and thyroid glands of the treated diabetic rats (Group 3 and Group 4) compared with the levels in non-treated diabetic rats (Group 3).<\/p>\n\n\n\n

Table 3: Effects of Metformin and dilute AHA oil treatments on Hsp70 expression in diabetic rats.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Hsp70 Expression<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

L<\/strong>iver<\/strong><\/p>\n<\/td>\n

\n

Kidney<\/strong><\/p>\n<\/td>\n

\n

T<\/strong>hyroid
gland<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Group 3 1<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 4 2<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 5 3<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 3 1<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 4 2<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 5 3<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 3 1<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 4 2<\/sup><\/strong><\/p>\n<\/td>\n

\n

Group 5 3<\/sup><\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

0.08*<\/p>\n<\/td>\n

\n

0.90**<\/p>\n<\/td>\n

\n

0.70**<\/p>\n<\/td>\n

\n

0.15*<\/p>\n<\/td>\n

\n

0.93**<\/p>\n<\/td>\n

\n

0.60**<\/p>\n<\/td>\n

\n

0.10*<\/p>\n<\/td>\n

\n

0.80**<\/p>\n<\/td>\n

\n

0.5**<\/p>\n<\/td>\n<\/tr>\n

\n

0.10*<\/p>\n<\/td>\n

\n

0.89**<\/p>\n<\/td>\n

\n

0.69**<\/p>\n<\/td>\n

\n

0.13*<\/p>\n<\/td>\n

\n

0.90**<\/p>\n<\/td>\n

\n

0.70**<\/p>\n<\/td>\n

\n

0.09*<\/p>\n<\/td>\n

\n

0.79**<\/p>\n<\/td>\n

\n

0.49**<\/p>\n<\/td>\n<\/tr>\n

\n

0.09*<\/p>\n<\/td>\n

\n

0.80**<\/p>\n<\/td>\n

\n

0.71**<\/p>\n<\/td>\n

\n

0.15*<\/p>\n<\/td>\n

\n

0.89**<\/p>\n<\/td>\n

\n

0.59**<\/p>\n<\/td>\n

\n

0.08*<\/p>\n<\/td>\n

\n

0.75**<\/p>\n<\/td>\n

\n

0.52**<\/p>\n<\/td>\n<\/tr>\n

\n

0.11*<\/p>\n<\/td>\n

\n

0.95**<\/p>\n<\/td>\n

\n

0.76**<\/p>\n<\/td>\n

\n

0.16*<\/p>\n<\/td>\n

\n

0.92**<\/p>\n<\/td>\n

\n

0.58**<\/p>\n<\/td>\n

\n

0.11*<\/p>\n<\/td>\n

\n

0.81**<\/p>\n<\/td>\n

\n

0.55**<\/p>\n<\/td>\n<\/tr>\n

\n

0.10*<\/p>\n<\/td>\n

\n

0.93**<\/p>\n<\/td>\n

\n

0.75**<\/p>\n<\/td>\n

\n

0.12*<\/p>\n<\/td>\n

\n

0.91**<\/p>\n<\/td>\n

\n

0.62**<\/p>\n<\/td>\n

\n

0.99*<\/p>\n<\/td>\n

\n

0.82**<\/p>\n<\/td>\n

\n

0.49**<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

1<\/sup><\/strong> Rats with alloxan-induced diabetes, 2<\/sup><\/strong> Diabetic rats treated with Metformin. 3<\/sup><\/strong> Diabetic rats treated with dilute AHA oil.<\/p>\n

* Statistically significant when compared to the control group at \u03b1<\/em> = 0.05. ** Statistically significant when compared to the untreated diabetic group, i.e., Group 3, at \u03b1<\/em> = 0.05.<\/p>\n\n\n

Levels of expression of iNOS in rats of the control and diabetic groups<\/strong><\/p>\n\n\n\n

Diabetes resulted in a statistically significant (p <\/em>< 0.05) increase in the levels of iNOS expression in the livers, kidneys, and thyroid glands of the rats (Table 4). Diabetes affects the thyroid gland, liver, and kidney at the molecular level.<\/p>\n\n\n\n

Table 4: Levels of expression of iNOS in rats of the control and diabetic groups. <\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

iNOS Expression<\/p>\n<\/td>\n<\/tr>\n

\n

Liver<\/p>\n<\/td>\n

\n

Kidney<\/p>\n<\/td>\n

\n

Thyroid gland<\/p>\n<\/td>\n<\/tr>\n

\n

Control rats<\/p>\n<\/td>\n

\n

Diabetic rats<\/p>\n<\/td>\n

\n

Control rats<\/p>\n<\/td>\n

\n

Diabetic rats<\/p>\n<\/td>\n

\n

Control rats<\/p>\n<\/td>\n

\n

Diabetic rats<\/p>\n<\/td>\n<\/tr>\n

\n

0.01<\/p>\n<\/td>\n

\n

0.75<\/p>\n<\/td>\n

\n

0.06<\/p>\n<\/td>\n

\n

0.62<\/p>\n<\/td>\n

\n

0.12<\/p>\n<\/td>\n

\n

0.62<\/p>\n<\/td>\n<\/tr>\n

\n

0.02<\/p>\n<\/td>\n

\n

0.76<\/p>\n<\/td>\n

\n

0.04<\/p>\n<\/td>\n

\n

0.74<\/p>\n<\/td>\n

\n

0.13<\/p>\n<\/td>\n

\n

0.59<\/p>\n<\/td>\n<\/tr>\n

\n

0.02<\/p>\n<\/td>\n

\n

0.77<\/p>\n<\/td>\n

\n

0.07<\/p>\n<\/td>\n

\n

0.83<\/p>\n<\/td>\n

\n

0.14<\/p>\n<\/td>\n

\n

0.70<\/p>\n<\/td>\n<\/tr>\n

\n

0.03<\/p>\n<\/td>\n

\n

0.82<\/p>\n<\/td>\n

\n

0.07<\/p>\n<\/td>\n

\n

0.56<\/p>\n<\/td>\n

\n

0.09<\/p>\n<\/td>\n

\n

0.69<\/p>\n<\/td>\n<\/tr>\n

\n

0.04<\/p>\n<\/td>\n

\n

0.79<\/p>\n<\/td>\n

\n

0.05<\/p>\n<\/td>\n

\n

0.70<\/p>\n<\/td>\n

\n

0.10<\/p>\n<\/td>\n

\n

0.63<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n

Effects of Metformin and dilute AHA oil on levels of expression of iNOS<\/strong><\/p>\n\n\n\n

Table 5 illustrates that the rats’ thyroid glands, livers, and kidneys all had considerably lower levels of iNOS expression (p < 0.05) after receiving both the Metformin and diluted AHA oil treatments.<\/p>\n\n\n\n

Table 5: Results of analysis of differences in levels of iNOS expression between rats of the control group and those receiving Metformin and dilute AHA oil treatments.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

iNOS Expression<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Liver<\/strong><\/p>\n<\/td>\n

\n

Kidney<\/strong><\/p>\n<\/td>\n

\n

Thyroid gland<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Diabetic<\/strong>
rats<\/strong><\/p>\n<\/td>\n

\n

Metformin<\/strong><\/p>\n<\/td>\n

\n

Dilute<\/strong>
AHA oil<\/strong><\/p>\n<\/td>\n

\n

Diabetic<\/strong>
rats<\/strong><\/p>\n<\/td>\n

\n

Metformin<\/strong><\/p>\n<\/td>\n

\n

Dilute <\/strong>
AHA oil<\/strong><\/p>\n<\/td>\n

\n

Diabetic<\/strong>
rats<\/strong><\/p>\n<\/td>\n

\n

Metformin<\/strong><\/p>\n<\/td>\n

\n

Dilute<\/strong>
AHA oil<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

0.75*<\/p>\n<\/td>\n

\n

0.19**<\/p>\n<\/td>\n

\n

0.23**<\/p>\n<\/td>\n

\n

0.62*<\/p>\n<\/td>\n

\n

0.22**<\/p>\n<\/td>\n

\n

0.28**<\/p>\n<\/td>\n

\n

0.62*<\/p>\n<\/td>\n

\n

0.41**<\/p>\n<\/td>\n

\n

0.50**<\/p>\n<\/td>\n<\/tr>\n

\n

0.76*<\/p>\n<\/td>\n

\n

0.20**<\/p>\n<\/td>\n

\n

0.23**<\/p>\n<\/td>\n

\n

0.74*<\/p>\n<\/td>\n

\n

0.20**<\/p>\n<\/td>\n

\n

0.25**<\/p>\n<\/td>\n

\n

0.59*<\/p>\n<\/td>\n

\n

0.39**<\/p>\n<\/td>\n

\n

0.49**<\/p>\n<\/td>\n<\/tr>\n

\n

0.77*<\/p>\n<\/td>\n

\n

0.18**<\/p>\n<\/td>\n

\n

0.22**<\/p>\n<\/td>\n

\n

0.83*<\/p>\n<\/td>\n

\n

0.23**<\/p>\n<\/td>\n

\n

0.26**<\/p>\n<\/td>\n

\n

0.70*<\/p>\n<\/td>\n

\n

0.30**<\/p>\n<\/td>\n

\n

0.51**<\/p>\n<\/td>\n<\/tr>\n

\n

0.82*<\/p>\n<\/td>\n

\n

0.17**<\/p>\n<\/td>\n

\n

0.24**<\/p>\n<\/td>\n

\n

0.56*<\/p>\n<\/td>\n

\n

0.15**<\/p>\n<\/td>\n

\n

0.24**<\/p>\n<\/td>\n

\n

0.69*<\/p>\n<\/td>\n

\n

0.40**<\/p>\n<\/td>\n

\n

0.48**<\/p>\n<\/td>\n<\/tr>\n

\n

0.79*<\/p>\n<\/td>\n

\n

0.16**<\/p>\n<\/td>\n

\n

0.25**<\/p>\n<\/td>\n

\n

0.70*<\/p>\n<\/td>\n

\n

0.18**<\/p>\n<\/td>\n

\n

0.23**<\/p>\n<\/td>\n

\n

0.63*<\/p>\n<\/td>\n

\n

0.42**<\/p>\n<\/td>\n

\n

0.52**<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n
\"\"<\/td>\n\n

Figure 1<\/strong>: Levels of HSP70 expression in the thyroid gland from the rate, A: control (HSP70 staining arrow). B: diabetic rats (HSP70 staining arrow).<\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
\"\"<\/td>\n\n

Figure 2<\/strong>: Levels of INOS expression in the thyroid gland from the rate, A: control (INOS<\/strong> staining arrow). B: diabetic rats <\/strong>(INOS<\/strong> staining arrow). <\/strong><\/p>\n

<\/p>\n

Click here to view Figure<\/a><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n

 Discussion <\/strong><\/p>\n\n\n\n

The thyroid is one of the major endocrine\nglands in the body. It affects how quickly the body utilizes energy, makes\nproteins, and influences its response to other hormones 21<\/sup>. With\nthe production of thyroid hormones T4 and T3, it aids in these processes. The\ngrowth and operation of several other bodily systems are impacted by these,\nwhich also regulate metabolism. Tyrosine and iodine are used to make T3 and T422<\/sup>. The\nthyroid gland also generates calcitonin, which is a hormone that regulates calcium\nlevels. The hypothalamus and pituitary glands regulate thyroid function23<\/sup>. TSH secreted by\nthe anterior pituitary, which is produced by TRH release by hypothalamus,\ncontrols the synthesis of T4 and T3. In a negative feedback loop, the thyroid\nand thyrotropes produce less TSH when T4 levels are high and vice versa24<\/sup>. <\/p>\n\n\n\n

Thyroid disorders are two to three\ntimes more common in patients with diabetes than in non-diabetic individuals. It also increases with age\nand is significantly impacted by autoimmune diabetes mellitus. In addition, they were substantially\ngreater in female patients than in male patients. If a thyroid disease is\nlinked to deterioration functions, its clinical significance, especially for\ndiabetic individuals, increases dramatically. This is because\ndeclining functions consistently lead to several issues related to metabolic compensation of\ndiabetes25<\/sup>.\nThe two most dangerous outcomes of thyrotoxicosis are the development of potentially fatal\nketoacidosis and an increased frequency of hypoglycemia in hypothyroidism.\nResearch has demonstrated correlations between DM and several endocrine\ndisorders, including gonadal dysfunction26<\/sup>. It has additionally been demonstrated\nthat there are physiological and molecular connections between insulin and how\niodothyronines and insulin affect the metabolism of lipids, proteins, and\ncarbohydrates27<\/sup>.\nTriiodothyronine and tetraiodothynine are two thyroid hormones that serve as\ninsulin antagonists and indirectly enhance insulin activity. T3 and T4 levels are\noften reduced in people and experimental animals with diabetes26,27<\/sup>.Diabetes\ncauses alterations in hypothalamic thyrotropin-releasing hormone (TRH) excretion\nand pituitary thyrotropin (thyroid-stimulating hormone (TSH)) release and has\ndirect effect on the thyroid gland28<\/sup>. Serum T3 concentrations are known to decline\nin diabetic patients, possibly due to inhibition of peripheral 5\u00b4-deiodinase\nenzyme activity, which catalyzes conversion of T4 to T3. <\/p>\n\n\n\n

For thousands of years, conventional medicine has used natural\ntherapies to maintain the robust health of the endocrine system, promoting and\nregulating optimal hormone production and thyroid function29<\/sup>. Several\npublished clinical trials have confirmed the efficacy of various herbs in\nstrengthening the immune system and a healthy thyroid function. Thyroid\nhormones are required for metabolic homeostasis, and impaired thyroid function\ncan be a serious consequence of diabetes30<\/sup>. Thyroid function is mostly determined by\nserum T3 and T4 levels28,30<\/sup>.\nIn diabetic mice, the level of T3<\/sub> decreased was lower than that in\nthe control mice. The T3\/T4 ratio in the diabetic mice significantly decreased,\naccording to these findings. Abnormal T3 levels are a sign of reduced\nmicrosomal ability to convert T4 to T3, most likely due to the emergence of\noxidative conditions in many systemic non-thyroid disorders24,28<\/sup>. Therefore, we\nconclude that liver damage may be the mechanism underlying the observed\ndecrease in T3<\/sub> expression in diabetic mice. Diabetes suppresses\nthyroid hormones (T3<\/sub> and T4<\/sub>) and serum insulin levels\nthat regulate the basal metabolic rate31<\/sup>. <\/p>\n\n\n\n

Diabetic rats administered with dilute AHE oil or Metformin had\nsubstantially decreased T3, T4, and TSH levels compared to the control group (p\n< 0.05). Current research suggests that the diluted AHE oil has a moderating\nfunction during endocrine system disruptions. Related findings were reported in the literature study:\noral treatment of A. herba-alba<\/em> significantly increased thyroid blood\nlevels of T3 and TSH in the protective group compared to the control group. On\nthe other hand, it was revealed that AHA extract had a protective impact on\nserum T4 levels like that of the control. A. herba-alba<\/em> includes several\nphytochemicals, including phenols and flavonoids, which are known to have a\nvariety of pharmacological properties 37<\/sup>. A similar role can\nbe argued for Metformin\nin view of the study findings. While the exact reasons of thyroid dysfunction\nin diabetes mellitus are yet unclear, several elements of thyroid function can\nbe directly impacted by metabolic changes brought on by diabetes or by insulin\ndeficiency28,31<\/sup>.\n<\/p>\n\n\n\n

Our study\nshowed that the single dose of alloxan was effective in inducing DM in the early\nstages of type 2 DM. Serum T3<\/sub> and T4 <\/sub>levels dropped in\nshort-term diabetic rats. Similar results were found in literature32<\/sup>. This\ndemonstrates a shift in the variables that determine reduced thyroid hormone\nproduction during the early stages of insulinopeinia33<\/sup>. Short-term\ninsulinopeinia in diabetic mice cannot be attributed to decreased TSH\nactivation of the thyroid gland, according to researchers 33, 34<\/sup>. However,\ndilute AHA oil or Metformin\ntreatment independently returned blood T3 levels to normal levels, which\nappears to be related to its antioxidant activity. It is possible that the\neffect of the extract on raising thyroid hormone concentrations reflects its\ninfluence on increasing insulin secretion. Insulin stimulates hepatic T4<\/sub>\/T3<\/sub>\nconversion and improves the synthetic capacity of thyroid cells. Hence, the\npresent results suggest a role for dilute AHE oil or metformin. As a result,\nthe effect of dilute AHE oil on the increase in the level of hormones may\nindicate the influence on insulin secretion. Our findings indicate that dilute\nAHE oil participates in the peripheral control of thyroid function and may\nstimulate or enhance thyroid roles. However, further research is needed into\nthe processes and modes of activity.<\/p>\n\n\n\n

The results of this\ninvestigation demonstrated that diabetes significantly reduced Hsp70 expression\nin both the rat liver and kidney (p <\/em><\n0.05). This conclusion is consistent with earlier investigations that reveal a limited\nimpact of HSP70. This conclusion is consistent with earlier investigations that\nreveal a limited impact of HSP7035<\/sup>. We believe that diabetes may mediate its adverse\neffects by lowering the expression of Hsp70.<\/p>\n\n\n\n

Our results\nindicate that treatment with dilute AHA oil and Metformin substantially (p <\/em>< 0.05) raised the expression of Hsp70 in the livers, kidneys,\nand thyroid glands of rats. This finding may explain the positive changes\nembodied in lowered glucose levels and other associated chemicals, such as\nlipid profile. We believe that both treatments could restore the normal\nfunctions associated with Hsp70 and reverse some of the passive effects of\ndiabetes. In addition, iNOS expression was significantly increased (p<\/em> < 0.05) because of induced diabetes\nin the liver, kidney, and thyroid gland. However, its expression was\nsignificantly decreased (p <\/em>< 0.05)\nby both treatments. <\/p>\n\n\n\n

According to a research study, NO is involved in several critical body processes, including blood pressure regulation, brain neurotransmitter function, and immune system defense against viruses and bacteria34<\/sup>. But NO may also be produced excessively, or mis regulated, which adds to the etiology of several illnesses, including diabetes34<\/sup>.<\/p>\n\n\n\n

Conclusion <\/strong><\/p>\n\n\n\n

The\noutcomes of the current research indicate that the diluted AHE oil stimulates\nor enhances thyroid activity, and they also point to a potential role for the\noil in peripheral thyroid control. From a molecular point of view, Hsp70 and iNOS seem to act in a counteracting mechanism in both\ndisease and treatment. Therefore, these molecules are good targets for\ntherapeutic and clinical applications36<\/sup>.<\/p>\n\n\n\n

Data availability<\/strong><\/p>\n\n\n\n

 All data generated or analyzed during this study are\nincluded in this article.<\/p>\n\n\n\n

Acknowledgement<\/strong><\/p>\n\n\n\n

None<\/p>\n\n\n\n

Conflict of\nInterest<\/strong><\/p>\n\n\n\n

 The authors declare no conflict of interest.<\/p>\n\n\n\n

Funding Sources<\/strong> <\/p>\n\n\n\n

No funding agency has provided support for this research. <\/p>\n\n\n\n

References<\/strong><\/p>\n\n\n\n

  1. Bora KS, Sharma A. The genus Artemisia: a comprehensive review. Pharmaceutical biology. 2011 Jan 1;49(1):101-9.
    CrossRef<\/a><\/li>
  2. Alshehri MA, Panneerselvam C, Murugan K, Trivedi S, Mahyoub JA, Maggi F, Sut S, Dall’Acqua S, Canale A, Benelli G. The desert wormwood (Artemisia herba-alba)\u2013From Arabian folk medicine to a source of green and effective nanoinsecticides against mosquito vectors. Journal of photochemistry and photobiology B: biology. 2018 Mar 1;180:225-34.
     CrossRef <\/a><\/li>
  3. Sayyah M, Nadjafnia L, Kamalinejad M. Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil. Journal of ethnopharmacology. 2004 Oct 1;94(2-3):283-7.
     CrossRef <\/a><\/li>
  4. 4Mi\u00f1o JH, Moscatelli V, Acevedo C, Ferraro G. Psychopharmacological effects of Artemisia copa aqueous extract in mice. Pharmaceutical Biology. 2010 Dec 1;48(12):1392-6.
     CrossRef <\/a><\/li>
  5. Mahboubi M. Artemisia sieberi Besser essential oil and treatment of fungal infections. Biomedicine & pharmacotherapy. 2017 May 1; 89:1422-30.
     CrossRef <\/a><\/li>
  6. Mohammed HA, Qureshi KA, Ali HM, Al-Omar MS, Khan O, Mohammed SA. Bio-evaluation of the wound healing activity of Artemisia judaica L. as part of the plant\u2019s use in traditional medicine; phytochemical, antioxidant, anti-inflammatory, and antibiofilm properties of the plant\u2019s essential oils. Antioxidants. 2022 Feb 8;11(2):332.
     CrossRef <\/a><\/li>
  7. Afifi-Yazar FU, Kasabri V, Abu-Dahab R. Medicinal plants from Jordan in the treatment of cancer: traditional uses vs. in vitro and in vivo evaluations\u2013Part 1. Planta medica. 2011 Jul;77(11):1203-9.
     CrossRef <\/a><\/li>
  8. Al-Mazari, I. S., Alsarhan, A., Amawi, K. F., Deeb, A. S. A., Al-Emerieen, A. A., & Alkhatib, A. J. Compound expression of inducible nitric oxide synthase (inos) and p53 in prostate tissue of diabetic rats. (2021).<\/li>
  9. Toda N, Kishioka S, Hatano Y, Toda H, Warner DS, Warner MA. Modulation of opioid actions by nitric oxide signaling. The Journal of the American Society of Anesthesiologists. 2009 Jan 1;110(1):166-81.
     CrossRef <\/a><\/li>
  10. Garme Y, Moudi M, Saravani R, Galavi H. Nitric oxide synthase 2 polymorphisms (rs2779248T\/C and rs1137933C\/T) and the risk of Type 2 diabetes in Zahedan, Southeastern Iran. Iranian Journal of Public Health. 2018 Nov;47(11):1734.<\/li>
  11. Mulyani WR, Sanjiwani MI, Sandra, Prabawa IP, Lestari AA, Wihandani DM, Suastika K, Saraswati MR, Bhargah A, Manuaba IB. Chaperone-based therapeutic target innovation: Heat shock protein 70 (HSP70) for Type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity. 2020 Feb 27:559-68.
     CrossRef <\/a><\/li>
  12. Malyshev I, Malyshev I. HSP70 in Damaged Cells. Immunity, Tumors and Aging: The Role of HSP70. 2013:31-45.
     CrossRef <\/a><\/li>
  13. Krause M, Bock PM, Takahashi HK, Homem De Bittencourt Jr PI, Newsholme P. The regulatory roles of NADPH oxidase, intra-and extra-cellular HSP70 in pancreatic islet function, dysfunction and diabetes. Clinical Science. 2015 Jun 1;128(11):789-803.
     CrossRef <\/a><\/li>
  14. Shamsi MM, Mahdavi M, Quinn LS, Gharakhanlou R, Isanegad A. Effect of resistance exercise training on expression of Hsp70 and inflammatory cytokines in skeletal muscle and adipose tissue of STZ-induced diabetic rats. Cell stress and chaperones. 2016 Sep 1;21(5):783-91.
     CrossRef <\/a><\/li>
  15. Hamann I, Seidlova-Wuttke D, Wuttke W, K\u00f6hrle J. Effects of isoflavonoids and other plant-derived compounds on the hypothalamus\u2013pituitary\u2013thyroid hormone axis. Maturitas. 2006 Nov 1;55:S14-25.
     CrossRef <\/a><\/li>
  16. 16Mohamed AE, Abdel-Aziz AF, El-Sherbiny EM, Mors R. Anti-diabetic effect of Aloe vera juice and evaluation of thyroid function in female diabetic rats. Bioscience Research. 2009 Jan 1;6(1):28-34.<\/li>
  17. Irshaid F, Mansi K, Bani-Khaled A, Aburjia T. Hepatoprotetive, cardioprotective and nephroprotective actions of essential oil extract of Artemisia sieberi in alloxan induced diabetic rats. Iranian journal of pharmaceutical research: IJPR. 2012;11(4):1227.<\/li>
  18. A. khaled S. Bani-khaled, K. Mansi, and T. Aburjai, Effects of Oral Administration of Volatile Oil Extract of Artemisia Sieberi (A. Herba Alba) on the Activity of Hypothalamic Pituitary Thyroid (HPT) Axis in Diabetic Induced Rats<\/em>. Al Al-Bayt University, 2000.<\/li>
  19. Al-khatib A. Co-expression of iNOS and HSP70 in diabetes type 1 makes a rational hypothesis to explain the diabetic neuropathy. European scientific journal. 2013 Jan 28;9(3)..<\/li>
  20. Alsarhan A, Mansi K, Aburjai T, Al-Khatib A, Alzweiri M, Sultana N. Hsp70 and iNOS biomarkers in evaluating the healing properties of Rubia tinctorum. European Scientific Journal. 2013 May 1;9(15):1857-7881.<\/li>
  21. Pitt-Rivers R, Tata JR. The thyroid hormones. Elsevier; 2013 Oct 22.<\/li>
  22. Wr\u00f3blewski M, Wr\u00f3blewska J, Nuszkiewicz J, Paw\u0142owska M, Weso\u0142owski R, Wo\u017aniak A. The role of selected trace elements in oxidoreductive homeostasis in patients with thyroid diseases. International Journal of Molecular Sciences. 2023 Mar 2;24(5):4840.
     CrossRef <\/a><\/li>
  23. Sai Kumar BA. Hormonal regulation of metabolism, water, and minerals. InTextbook of Veterinary Physiology 2023 ,Sep 1 (pp. 391-415).
     CrossRef <\/a><\/li>
  24. L. H. Duntas, \u201cEnvironmental Endocrinology and the Hypothalamus-Pituitary-Thyroid Axis,\u201d in Environmental Endocrinology and Endocrine Disruptors: Endocrine and Endocrine-targeted Actions and Related Human Diseases<\/em>, Springer, 2023, pp. 1\u201319.
     CrossRef <\/a><\/li>
  25. Grubi\u0161i\u0107 B, \u0160vitek L, Ormanac K, Sabo D, Mihaljevi\u0107 I, Bili\u0107-\u0106ur\u010di\u0107 I, Kolari\u0107 TO. Molecular Mechanisms Responsible for Diabetogenic Effects of COVID-19 Infection\u2014Induction of Autoimmune Dysregulation and Metabolic Disturbances. International journal of molecular sciences. 2023 Jul 18;24(14):11576.
     CrossRef <\/a><\/li>
  26. Krentz AJ. Classic endocrine disorders: implications for cardiovascular disease. InCardiovascular Endocrinology and Metabolism 2023 Jan 1 (pp. 233-270).
    CrossRef <\/a><\/li>
  27. La Fauci D, Bionda A, Liotta L, Crepaldi P, Chiofalo V, Lopreiato V, Fazio E. Effects of pregnancy and lactation on thyroid hormones, insulin, and metabolic blood parameters of modicana dairy cows. Large Animal Review. 2023 Feb 6;29(1):1-7.<\/li>
  28. KUTLU Z, KAMACI AD. The Relationship Between Euthyroid, Hyperthyroid, Hypothyroid, and Type 2 Diabetes. Pharmata. 2023 Oct 9;3(4):105-11.
     CrossRef <\/a><\/li>
  29. Khan KM, Hameed S, Shamim S. Natural products to cure bad breath. Pharmacological Studies in Natural Oral Care. 2023 Oct 3:217-52.
     CrossRef <\/a><\/li>
  30. Macvanin MT, Gluvic Z, Zafirovic S, Gao X, Essack M, Isenovic ER. The protective role of nutritional antioxidants against oxidative stress in thyroid disorders. Frontiers in Endocrinology. 2023 Jan 4;13:1092837.
     CrossRef <\/a><\/li>
  31. Le Moli R, Malandrino P, Russo M, Tumino D, Piticchio T, Naselli A, Rapicavoli V, Belfiore A, Frasca F. Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study. Endocrinology, Diabetes & Metabolism. 2023 Mar;6(2):e406.
     CrossRef <\/a><\/li>
  32. Shi H, Korejo NA, Kamboh AA, Korejo RA, Shi F. Effects of hyperthyroidism and diabetes mellitus on spermatogenesis in peri-and post-pubertal mice. Frontiers in Endocrinology. 2023 Aug 15;14 P:1191571.
     CrossRef <\/a><\/li>
  33. Nascimento-Saba CC, Breitenbach MM, Rosenthal D. Pituitary-thyroid axis in short-and long-term experimental diabetes mellitus. Brazilian journal of medical and biological research. 1997;30:269-74.
     CrossRef <\/a><\/li>
  34. Yuen KC, Johannsson G, Ho KK, Miller BS, Bergada I, Rogol AD. Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis. Endocrine Connections. 2023 Jul 1;12(7).
    CrossRef <\/a><\/li>
  35. Smolka MB, Zoppi CC, Alves AA, Silveira LR, Marangoni S, Pereira-Da-Silva L, Novello JC, Macedo DV. HSP72 as a complementary protection against oxidative stress induced by exercise in the soleus muscle of rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2000 Nov 1;279(5):R1539-45.
     CrossRef <\/a><\/li>
  36. Barcellos LF, Ramsay PP, Caillier SJ, Sawcer S, Haines J, Schmidt S, Pericak-Vance M, Compston DA, Gabatto P, Hauser SL, Oksenberg JR. Genetic variation in nitric oxide synthase 2A (NOS2A) and risk for multiple sclerosis. Genes & Immunity. 2008 Sep;9(6):493-500.
     CrossRef <\/a><\/li>
  37. El-Sawi, N.M., El-Hady, O.M., El-Aref, A.H. and Hefny Gad, M.,. Estimation of the Efficacy of Oral Administration of Egyptian Artemisia herba-alba Extract in Combating Thyroid Dysfunction in Diabetic Male Rats. Sohag Journal of Sciences, 9(3), pp.234-240, 2024
     CrossRef <\/a><\/li><\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Artemisia sieberi (A. herba-alba) belongs to the Asteraceae (Compositae) […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[115],"tags":[],"class_list":["post-59005","post","type-post","status-publish","format-standard","hentry","category-vol17no2"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/59005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=59005"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/59005\/revisions"}],"predecessor-version":[{"id":59623,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/59005\/revisions\/59623"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=59005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=59005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=59005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}